---
title: "Autologous Vs Allogeneic: Critical 2026 Pathways"
description: "Autologous vs Allogeneic is not a technical footnote. The distinction decides which FDA pathway applies and which state rules a provider has to satisfy."
url: "https://savemyfat.com/autologous-vs-allogeneic-cell-sources/"
---

# Autologous Versus Allogeneic Cell Sources: Why the Distinction Shapes Regulatory Pathways

#### Table of Contents

- [Oscar Tellez](https://savemyfat.com/author/oscartellez/)
- [August 14, 2026](https://savemyfat.com/2026/08/14/)
- 10:00 am

![Autologous vs allogeneic sourcing shown by two cryovials on a frosted metal tray](https://savemyfat.com/wp-content/uploads/2026/07/August-14.png)Autologous versus allogeneic cell sources: why the distinction shapes regulatory pathways 2

The difference between autologous vs allogeneic stem cells sits at the center of federal tissue regulation. One word can decide whether a product is regulated solely as a 361 human cell and tissue product or travels the longer biologic route. Two 2026 state laws now draw that same line.

**TLDR:** Autologous means the tissue returns to the person it came from, and allogeneic means it goes to someone else. Under 21 CFR 1271.10(a), all four criteria must be met for regulation solely as a 361 HCT/P, and the fourth turns on source. A product with a systemic effect, or one dependent on the metabolic activity of living cells, fits only if the use is autologous, allogeneic in a first-degree or second-degree blood relative, or reproductive. Tennessee and Wyoming tier their 2026 standards the same way. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit.

**Important Disclaimer:** Save My Fat is a connector service linking patients and providers to a U.S. tissue bank. Save My Fat does not provide FDA-approved treatments or cures and does not guarantee eligibility, access, or clinical benefit. Adipose tissue and stromal vascular fraction are investigational and not FDA approved. Regulatory classification is a legal determination made by the FDA, and in some cases by state boards, so nothing here is legal advice. This content is for educational purposes only, and readers should consult their own licensed healthcare professionals before acting on it.

---

Two vials can hold cells from the same tissue type, processed in the same laboratory on the same day. One goes back to the person it came from, and the other goes to someone else. Under a microscope the cells look alike, but the paperwork that follows them does not.

That difference has a name in federal regulation. It sits in the last of four criteria that decide whether a product is regulated solely under Section 361 of the Public Health Service Act, or as a drug or biological product requiring premarket review. Until 2026 that split lived only in federal text. Then two states wrote it into their statutes.

## Autologous vs Allogeneic Stem Cells: What Each Term Means

Autologous means the tissue returns to the same person it came from, so the donor and the recipient are one individual. Allogeneic means the tissue moves from one person to another, whether that person is a relative, a matched donor, or an anonymous one. The label follows the relationship in every case.

The two words describe a relationship, not a processing method or a measure of cell quality. A laboratory can run identical steps on both. What changes is the immunology, the consent paperwork, and the regulatory pathway. The federal rules in [21 CFR Part 1271](/what-is-21-cfr-part-1271-and-why-it-governs-tissue/) are where that last consequence lives.

---

## The Four Criteria in 21 CFR 1271.10(a) Are Cumulative

The FDA does not weigh these criteria against each other. All four must be met, so failing one moves a product out of the 361 pathway entirely, no matter how cleanly it satisfies the other three. That is what cumulative means here. The [regulation at section 1271.10](https://www.ecfr.gov/current/title-21/section-1271.10) lists them in order.

The first criterion is minimal manipulation, meaning processing does not alter the relevant biological characteristics of the cells. The second is homologous use only, shown by labeling, advertising, or other indications of objective intent. The third bars combination with another article, except water, crystalloids, or a sterilizing, preserving, or storage agent that raises no new clinical safety concerns. The first three never ask who receives the product, and only the fourth asks where the tissue is going.

Criteria one and two are worth understanding before source ever comes up. The [minimal manipulation standard](/what-minimally-manipulated-really-means-under-1271/) is defined at [section 1271.3](https://www.ecfr.gov/current/title-21/section-1271.3), which uses separate wording for structural tissue. The [homologous use criterion](/homologous-use-361-criterion-physicans-cant-ignore/) asks whether a product performs the same basic function in the recipient that it performed in the donor.

---

## Criterion Four: The Systemic Effect and Autologous Use Test

The fourth criterion is written as an either/or, and the structure is easy to misread. A product with a systemic effect, or one whose primary function depends on the metabolic activity of living cells, can sit inside the 361 pathway only if it is for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use. Products without that effect or dependence clear the criterion outright.

Once a product carries either feature, the door narrows to three uses, two of them defined by the donor and recipient relationship. Allogeneic products frequently leave the 361 pathway here, because cells from an unrelated donor that act through living cell activity fit none of the three. The FDA then regulates the product as a drug, device, or biological product, as its [tissue product questions and answers](https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/tissue-and-tissue-product-questions-and-answers) page explains.

---

## State Law Now Mirrors the Federal Split

For years, state stem cell statutes ignored source entirely. Florida, Georgia, and Utah each wrote rules that apply the same way whether a product came from the patient or from a donor. Two 2026 laws broke that pattern and imported the federal logic into their own product standards, and the change is recent enough to be easy to miss.

Tennessee moved first in substance. [Public Chapter 1016](https://publications.tnsosfiles.com/acts/114/pub/pc1016.pdf), effective July 1, 2026, tiers its product standards by source. Allogeneic product must come from a facility giving the physician proof of FDA registration, while autologous product needs a facility holding a CLIA certificate of compliance. Storage no higher than minus 80 degrees Celsius applies unless the product is autologous, and the viability rules carve out autologous too.

Those thresholds are greater than 90 percent viability on a pre-thaw certificate of analysis and no less than 80 percent on a post-thaw viability analysis report. Both numbers exempt autologous product. Tennessee is the only state setting numeric thresholds at all, so no percentage should ever be attributed to another state.

Wyoming went further and wrote the line into its scope. The [Stem Cell Freedom Act](https://www.wyoleg.gov/2026/Enroll/SF0048.pdf), effective July 1, 2026, covers autologous mesenchymal stem cells only and does not reach allogeneic birth tissue. It sets four preconditions: current IRB approval or investigational status, manufacture under good manufacturing practice, an existing physician-patient relationship, and physician registration with the state board.

The five states with recent sourcing statutes now fall into two camps. Two read source before applying a standard, and three apply one standard to everything. The table compares how each one handles the question.

State law Draws the autologous line? How source changes the requirement

Tennessee, Public Chapter 1016 Yes, tiered standards Allogeneic needs proof of FDA registration, autologous needs a CLIA certificate of compliance, and the minus 80 C rule plus both viability thresholds exempt autologous

Wyoming, Stem Cell Freedom Act Yes, scope limit Covers autologous mesenchymal stem cells only, not allogeneic birth tissue

Georgia, Act 453 No Facility registration or accreditation applies to any source

Florida, Chapter 2025-185 No Cumulative facility conditions and a post-thaw viability report apply to any source

Utah, Code 58-1-512 No Notice, consent contents, and the 2026 supplier duty apply to any source

A compliance checklist built for one of these states will not answer a question in another. Tennessee and Wyoming ask about source first, while the other three never ask it at all.

---

## What the Split Means for Banked Adipose Tissue

Tissue banked from your own body is autologous by definition. That is a classification fact, not an approval, and it connects no one to a therapy. It means only that if a future use is ever considered, criterion four is already answered for that person, while the other three criteria and every clinical judgment stay open.

The regulation also names allogeneic use in a first-degree or second-degree blood relative, and it defines those degrees itself, so no tissue bank decides who counts. That language creates a possibility for some families, not a guarantee for any of them. Eligibility would still depend on the remaining criteria and a physician’s judgment. Households weighing [family eligibility rules](/family-eligibility-for-banked-adipose-tissue/) or [couples and family banking](/banking-together-as-couples-and-families/) should treat every step as conditional.

---

## What the Distinction Does Not Change

Meeting all four criteria means a product is regulated solely under Section 361 without premarket review, not that the FDA reviewed and approved it, and it permits no medical claim. The [FDA consumer alert](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes) states that blood-forming stem cells from cord blood are the only approved stem cell products and that no exosome product is FDA approved.

State permission is a separate layer again. Florida’s [Chapter 2025-185](https://www.flsenate.gov/Session/Bill/2025/1768/BillText/er/HTML) allows non-FDA-approved stem cell therapy only within orthopedics, wound care, or pain management, which shows how far state authorization can sit from federal status. Adipose-derived cells and stromal vascular fraction remain under clinical investigation, the evidence is preliminary, and outcomes cannot be predicted.

---

## Frequently Asked Questions

### What is the practical difference between autologous and allogeneic cell sources?

Autologous means the donor and the recipient are the same person, while allogeneic means the cells move to a different person. Processing steps can be identical, so the difference is a relationship rather than a technique. That relationship changes the immunology, the consent documents, and the federal pathway.

### Why does the FDA treat autologous use differently under Section 361?

The fourth criterion in 21 CFR 1271.10(a) allows a product with a systemic effect, or one dependent on the metabolic activity of living cells, to stay in the 361 pathway only for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

### Does banking your own fat make future use automatically autologous?

Tissue collected from you and returned to you is autologous by definition, so that one criterion is satisfied. It is not automatic approval of anything else. The other three criteria still apply, and a licensed physician still decides what is appropriate at the time.

### What is the first-degree or second-degree blood relative exception?

It is language inside the fourth criterion. A product with a systemic effect or a dependence on living cell activity can remain in the 361 pathway when the use is allogeneic in a first-degree or second-degree blood relative. The regulation defines those degrees, and it does not guarantee eligibility, access, or clinical benefit to any relative.

### Does this distinction affect family banking decisions?

It gives families a reason to understand the regulation before deciding anything. Each person’s own tissue is autologous to that person, and the blood relative language is a possibility written into federal text rather than a promise. Families should review it with counsel and their own licensed healthcare professionals.

### Do state laws treat autologous and allogeneic products differently?

Two of them do. Tennessee tiers its 2026 product standards by source, and Wyoming limits its act to autologous mesenchymal stem cells only. Georgia, Florida, and Utah apply their requirements the same way regardless of source, so providers cannot reuse one checklist across all five states.

---

## Key Takeaways

The autologous and allogeneic labels describe who receives the tissue, not how it was processed. All four criteria in 21 CFR 1271.10(a) must be met for regulation solely as a 361 HCT/P. The fourth allows a product with a systemic effect, or one dependent on living cell metabolism, to remain there only for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

State law now echoes that split. Tennessee tiers registration, storage, and viability requirements by source, and Wyoming covers autologous mesenchymal stem cells only, while Georgia, Florida, and Utah draw no such line. Tissue you bank is autologous to you, and relatives may be eligible under the federal criteria as a possibility rather than a guarantee. Adipose-derived cells remain investigational and outcomes cannot be predicted.

Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.

Patients weighing adipose tissue banking for potential future use can review [current pricing](https://savemyfat.com/pricing/) or [contact our team](/contact-us/) with questions about collection and storage logistics.

---

*Save My Fat partners with L2 Bio for laboratory processing and storage.*

*This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about banking, treatment, or research participation.*

**About the author:** Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.

**Related guide:** [FDA adipose tissue regulation](https://savemyfat.com/fda-regulation-adipose-tissue/).

[PrevPreviousWhat Cell Passage Number Means and Why It Matters for Any Future Research Use](https://savemyfat.com/passage-number-mesenchymal-stem-cells/)

[NextCartilage Regeneration Research in 2026: A Patient’s Guide to What Is Being StudiedNext](https://savemyfat.com/cartilage-regeneration-research-2026/)

Providers

### [Urologist Guide to Adipose Banking and the Erectile Dysfunction Research Landscape](https://savemyfat.com/erectile-dysfunction-research-adipose-banking/)

 [Read More »](https://savemyfat.com/erectile-dysfunction-research-adipose-banking/)

Oscar Tellez 08/23/2026 10:00 AM

Providers

### [Dermatologist Guide to Adipose Banking: What the Research Landscape Looks Like in 2026](https://savemyfat.com/dermatologist-adipose-banking-guide/)

 [Read More »](https://savemyfat.com/dermatologist-adipose-banking-guide/)

Oscar Tellez 08/22/2026 10:00 AM

Clinical Trials

### [What Happens If a Clinical Trial for Adipose-Derived Cells Is Terminated Early](https://savemyfat.com/terminated-clinical-trial-what-it-means/)

 [Read More »](https://savemyfat.com/terminated-clinical-trial-what-it-means/)

Oscar Tellez 08/21/2026 10:00 AM

Clinical Trials

### [The Multiple System Atrophy Trial Landscape Beyond Mayo Clinic: What Else Is Being Studied](https://savemyfat.com/multiple-system-atrophy-clinical-trials-2026/)

 [Read More »](https://savemyfat.com/multiple-system-atrophy-clinical-trials-2026/)

Oscar Tellez 08/20/2026 10:00 AM

Regulation

### [Ryoncil in 2026: What Changed Since the First FDA-Approved MSC Therapy](https://savemyfat.com/ryoncil-2026-update-first-approved-msc-therapy/)

 [Read More »](https://savemyfat.com/ryoncil-2026-update-first-approved-msc-therapy/)

Oscar Tellez 08/19/2026 10:00 AM

Clinical Trials

### [NCT06002841 Explained: What This Registered Clinical Trial Is Studying](https://savemyfat.com/extracellular-vesicle-trial-nct06002841/)

 [Read More »](https://savemyfat.com/extracellular-vesicle-trial-nct06002841/)

Oscar Tellez 08/18/2026 10:00 AM

```json
[{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"#article","headline":"Autologous Vs Allogeneic: Critical 2026 Pathways","name":"Autologous Vs Allogeneic: Critical 2026 Pathways","datePublished":"2026-08-14T10:00:00-04:00","dateModified":"2026-08-14T10:00:00-04:00","description":"Autologous vs Allogeneic is not a technical footnote. The distinction decides which FDA pathway applies and which state rules a provider has to satisfy.","inLanguage":"en-US","image":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/07\/August-14.png","isPartOf":{"@id":"#webpage"},"author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"articleSection":"Adipose, Regulation, Stem Cells"},{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"Save My Fat","sameAs":["https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.linkedin.com\/company\/save-my-fat","https:\/\/www.instagram.com\/savemyfat\/","https:\/\/search.sunbiz.org\/Inquiry\/CorporationSearch\/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=SAVEMYFAT%20L260000005000&aggregateId=flal-l26000000500-32d6bf22-6788-4c6f-a062-b944408d7cda&searchTerm=SAVE%20MY%20LLC&listNameOrder=SAVEMY%20L250004108200"],"logo":{"@type":"ImageObject","@id":"https:\/\/savemyfat.com\/#logo","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2025\/12\/Blk-Txt-Blk-BG-SMF.svg","contentUrl":"https:\/\/savemyfat.com\/wp-content\/uploads\/2025\/12\/Blk-Txt-Blk-BG-SMF.svg","caption":"Save My Fat","inLanguage":"en-US","width":"500","height":"500"}},{"@type":"WebSite","@id":"https:\/\/savemyfat.com\/#website","url":"https:\/\/savemyfat.com","name":"Save My Fat","alternateName":"https:\/\/savemyfat.com","publisher":{"@id":"https:\/\/savemyfat.com\/#organization"},"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/07\/August-14.png","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/07\/August-14.png","width":"1250","height":"1250","caption":"Autologous vs Allogeneic sourcing shown by two cryovials on a frosted metal tray","inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https:\/\/savemyfat.com\/autologous-vs-allogeneic-cell-sources\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/savemyfat.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/savemyfat.com\/our-blog\/","name":"Our Blog"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/savemyfat.com\/category\/regulation\/","name":"Regulation"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/savemyfat.com\/autologous-vs-allogeneic-cell-sources\/","name":"Autologous Versus Allogeneic Cell Sources: Why the Distinction Shapes Regulatory Pathways"}}]},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/savemyfat.com\/autologous-vs-allogeneic-cell-sources\/#webpage","url":"https:\/\/savemyfat.com\/autologous-vs-allogeneic-cell-sources\/","name":"Autologous Vs Allogeneic: Critical 2026 Pathways","datePublished":"2026-08-14T10:00:00-04:00","dateModified":"2026-08-14T10:00:00-04:00","isPartOf":{"@id":"https:\/\/savemyfat.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/07\/August-14.png"},"inLanguage":"en-US","breadcrumb":{"@id":"https:\/\/savemyfat.com\/autologous-vs-allogeneic-cell-sources\/#breadcrumb"},"mainEntity":[{"@type":"Question","name":"What is adipose tissue banking?","acceptedAnswer":{"@type":"Answer","text":"Adipose tissue banking is the process of collecting, processing, and cryopreserving your own body fat for potential future use in FDA-regulated clinical research, Expanded Access programs, or approved therapies. It is a preservation service, not a treatment."}},{"@type":"Question","name":"Is adipose tissue banking FDA-approved?","acceptedAnswer":{"@type":"Answer","text":"Tissue banking as a preservation service is not a product requiring FDA approval. However, any future medical use of stored tissue must comply with FDA regulations at that time. Products derived from adipose tissue that undergo more than minimal manipulation typically require IND applications and a Biologics License Application before legal marketing."}}]}]},{"@context":"https:\/\/schema.org","@graph":[{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","description":"Oscar Tellez is the Founder of SaveMyFat, a national adipose tissue banking company that helps individuals preserve their own fat-derived stem cells for potential future use in FDA-regulated research pathways.","url":"https:\/\/savemyfat.com\/oscar-tellez","email":"info@savemyfat.com","image":{"@type":"ImageObject","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/05\/Oscar-Headshot-Rounded-1.png","width":"200","height":"200"},"worksFor":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"knowsAbout":["Adipose Tissue Banking","Stem Cell Cryopreservation","Regenerative Medicine","Fat-Derived Stem Cells","Expanded Access Pathways"],"sameAs":["https:\/\/savemyfat.com\/oscar-tellez","https:\/\/www.linkedin.com\/in\/o-tellez\/","https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.instagram.com\/savemyfat\/"]},{"@type":"Article","headline":"Autologous Versus Allogeneic Cell Sources: Why the Distinction Shapes Regulatory Pathways","url":"https:\/\/savemyfat.com\/autologous-vs-allogeneic-cell-sources\/","datePublished":"2026-08-14T10:00:00-04:00","dateModified":"2026-07-28T19:18:49-04:00","description":"Autologous means the tissue returns to the person it came from, and allogeneic means it goes to someone else. Under 21 CFR 1271.10(a), all four criteria must be met for regulation solely as a 361 HCT\/P, and the fourth turns on source. A product with a systemic effect, or one dependent on the metabolic activity of living cells, fits only if the use is autologous, allogeneic in a first-degree or second-degree blood relative, or reproductive. Tennessee and Wyoming tier their 2026 standards the same way. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit.","abstract":"Autologous means the tissue returns to the person it came from, and allogeneic means it goes to someone else. Under 21 CFR 1271.10(a), all four criteria must be met for regulation solely as a 361 HCT\/P, and the fourth turns on source. A product with a systemic effect, or one dependent on the metabolic activity of living cells, fits only if the use is autologous, allogeneic in a first-degree or second-degree blood relative, or reproductive. Tennessee and Wyoming tier their 2026 standards the same way. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit.","author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"speakable":{"@type":"SpeakableSpecification","cssSelector":["#tldr-summary"],"xpath":["\/\/*[@id=\"tldr-summary\"]"]}}]},{"@context":"https:\/\/schema.org","@type":"WebPage","@id":"https:\/\/savemyfat.com\/autologous-vs-allogeneic-cell-sources\/#webpage","url":"https:\/\/savemyfat.com\/autologous-vs-allogeneic-cell-sources\/","name":"Autologous vs Allogeneic Stem Cells: Why It Matters","speakable":{"@type":"SpeakableSpecification","cssSelector":[".smf-speakable"]}}]
```